Посилання

Ключові статті

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 [internet publication].Повний текст external link opens in a new window

Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD 2017 global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. http://www.goldcopd.org/ (last accessed 12 May 2017).Повний текст external link opens in a new window

Ford ES, Croft JB, Mannino DM, et al. COPD surveillance - United States, 1999-2011. Chest. 2013 Jul;144(1):284-305.Повний текст external link opens in a new windowРезюме external link opens in a new window

Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497-505.Резюме external link opens in a new window

Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398-420.Повний текст external link opens in a new windowРезюме external link opens in a new window

Celli BR, MacNee W, Agusti A, et al; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 Jun;23(6):932-46.Повний текст external link opens in a new windowРезюме external link opens in a new window

Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15.Повний текст external link opens in a new windowРезюме external link opens in a new window

Перелік літератури

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 [internet publication].Повний текст external link opens in a new window

2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD 2017 global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. http://www.goldcopd.org/ (last accessed 12 May 2017).Повний текст external link opens in a new window

3. Badgett RG, Tanaka DJ, Hunt DK, et al. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med. 1993 Feb;94(2):188-96.Резюме external link opens in a new window

4. Garcia-Pachon E. Paradoxical movement of the lateral rib margin (Hoover sign) for detecting obstructive airway disease. Chest. 2002 Aug;122(2):651-5.Резюме external link opens in a new window

5. Morgan AD, Rothnie KJ, Bhaskaran K, et al. Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. Thorax. 2018 Sep;73(9):877-9.Резюме external link opens in a new window

6. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis. 2008 Jul;12(7):703-8.Резюме external link opens in a new window

7. World Health Organization. Chronic obstructive pulmonary disease (COPD). 2018 [internet publication].Повний текст external link opens in a new window

8. Ford ES, Croft JB, Mannino DM, et al. COPD surveillance - United States, 1999-2011. Chest. 2013 Jul;144(1):284-305.Повний текст external link opens in a new windowРезюме external link opens in a new window

9. Li LS, Paquet C, Johnston K, et al. "What are my chances of developing COPD if one of my parents has the disease?" A systematic review and meta-analysis of prevalence of co-occurrence of COPD diagnosis in parents and offspring. Int J Chron Obstruct Pulmon Dis. 2017 Jan 24;12:403-15.Повний текст external link opens in a new windowРезюме external link opens in a new window

10. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000 Sep;55(9):789-94.Резюме external link opens in a new window

11. Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016 Sep;4(9):731-41.Резюме external link opens in a new window

12. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996 Feb;153(2):530-4.Резюме external link opens in a new window

13. Repine JE, Bast A, Lankhorst I; Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):341-57.Повний текст external link opens in a new windowРезюме external link opens in a new window

14. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):770-7.Повний текст external link opens in a new windowРезюме external link opens in a new window

15. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009 Dec;18(114):213-21.Повний текст external link opens in a new windowРезюме external link opens in a new window

16. Xu X, Weiss ST, Rijcken B, et al. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J. 1994 Jun;7(6):1056-61.Повний текст external link opens in a new windowРезюме external link opens in a new window

17. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497-505.Резюме external link opens in a new window

18. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Dec;162(6):2152-8.Повний текст external link opens in a new windowРезюме external link opens in a new window

19. Calverley PM, Anderson JA, Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 Feb 22;356(8):775-89.Повний текст external link opens in a new windowРезюме external link opens in a new window

20. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999 May;13(5):1109-14.Повний текст external link opens in a new windowРезюме external link opens in a new window

21. Gratziou C. Respiratory, cardiovascular and other physiological consequences of smoking cessation. Curr Med Res Opin. 2009 Feb;25(2):535-45.Резюме external link opens in a new window

22. Jing JY, Huang TC, Cui W, et al. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest. 2009 Apr;135(4):991-8.Резюме external link opens in a new window

23. World Health Organization. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415.Повний текст external link opens in a new windowРезюме external link opens in a new window

24. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010 Aug 1;182(3):325-31.Повний текст external link opens in a new windowРезюме external link opens in a new window

25. Gibson GJ, MacNee W. Chronic obstructive pulmonary disease: investigations and assessment of severity. Eur Respir Monogr. 1998;7:25-40.

26. Johnston KN, Potter AJ, Phillips A. Measurement properties of short lower extremity functional exercise tests in people with chronic obstructive pulmonary disease: systematic review. Phys Ther. 2017 Sep 1;97(9):926-43.Повний текст external link opens in a new windowРезюме external link opens in a new window

27. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398-420.Повний текст external link opens in a new windowРезюме external link opens in a new window

28. Wilt TJ, Niewoehner D, Kim C, et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (Summ). 2005 Aug;(121):1-7.Резюме external link opens in a new window

29. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997 Dec 15;127(12):1072-9.Резюме external link opens in a new window

30. Lemmens KM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med. 2009 May;103(5):670-91.Резюме external link opens in a new window

31. Kruis AL, Smidt N, Assendelft WJ, et al. Cochrane corner: is integrated disease management for patients with COPD effective? Thorax. 2014 Nov;69(11):1053-5.Повний текст external link opens in a new windowРезюме external link opens in a new window

32. Ward NS, Dushay KM. Clinical concise review: Mechanical ventilation of patients with chronic obstructive pulmonary disease. Crit Care Med. 2008 May;36(5):1614-9.Резюме external link opens in a new window

33. Roberts CM, Brown JL, Reinhardt AK, et al. Non-invasive ventilation in chronic obstructive pulmonary disease: management of acute type 2 respiratory failure. Clin Med (Lond). 2008 Oct;8(5):517-21.Повний текст external link opens in a new windowРезюме external link opens in a new window

34. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2008 Mar;133(3):756-66.Резюме external link opens in a new window

35. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(12):CD010257.Повний текст external link opens in a new windowРезюме external link opens in a new window

36. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother. 2008 Jul;9(10):1755-72.Резюме external link opens in a new window

37. Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008 Sep;62(3):442-50.Повний текст external link opens in a new windowРезюме external link opens in a new window

38. El Moussaoui R, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008 May;63(5):415-22.Резюме external link opens in a new window

39. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;(3):CD006897.Повний текст external link opens in a new windowРезюме external link opens in a new window

40. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013 Jun 5;309(21):2223-31.Повний текст external link opens in a new windowРезюме external link opens in a new window

41. Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010 Jun 16;303(23):2359-67.Повний текст external link opens in a new windowРезюме external link opens in a new window

42. Walters JA, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD001288.Повний текст external link opens in a new windowРезюме external link opens in a new window

43. Chen AM, Bollmeier SG, Finnegan PM, et al. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2008 Dec;42(12):1832-42.Резюме external link opens in a new window

44. Halpin DM, Vogelmeier C, Pieper MP, et al. Effect of tiotropium on COPD exacerbations: a systematic review. Respir Med. 2016 May;114:1-8.Повний текст external link opens in a new windowРезюме external link opens in a new window

45. Ismaila AS, Huisman EL, Punekar YS, et al. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015 Nov 16;10:2495-517.Повний текст external link opens in a new windowРезюме external link opens in a new window

46. Hilleman DE, Malesker MA, Morrow LE, et al. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:253-63.Повний текст external link opens in a new windowРезюме external link opens in a new window

47. Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018 Feb 1;178(2):229-38.Резюме external link opens in a new window

48. Gershon AS, Newman AM, Fischer HD, et al. Inhaled long-acting anticholinergics and urinary tract infection in individuals with COPD. COPD. 2017 Feb;14(1):105-12.Резюме external link opens in a new window

49. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008 Aug;134(2):255-62.Резюме external link opens in a new window

50. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008 Apr;102(4):479-87.Резюме external link opens in a new window

51. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009 Feb;6(1):17-25.Резюме external link opens in a new window

52. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008 Nov;102(11):1511-20.Резюме external link opens in a new window

53. Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017 Feb 10;(2):CD012066.Повний текст external link opens in a new windowРезюме external link opens in a new window

54. Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016 Apr;10(2):89-104.Повний текст external link opens in a new windowРезюме external link opens in a new window

55. Vogelmeier C, Hederer B, Glaab T, et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011 Mar 24;364(12):1093-103.Повний текст external link opens in a new windowРезюме external link opens in a new window

56. Decramer ML, Chapman KR, Dahl R, et al; INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013 Sep;1(7):524-33.Резюме external link opens in a new window

57. Celli B, Decramer M, Kesten S, et al. UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55.Повний текст external link opens in a new windowРезюме external link opens in a new window

58. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4):CD003902.Резюме external link opens in a new window

59. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014 May;145(5):981-91.Резюме external link opens in a new window

60. Radovanovic D, Mantero M, Sferrazza Papa GF, et al. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2016 Oct;10(10):1045-55.Резюме external link opens in a new window

61. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013 Dec;42(6):1484-94.Повний текст external link opens in a new windowРезюме external link opens in a new window

62. Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015 Apr;70(4):311-9.Повний текст external link opens in a new windowРезюме external link opens in a new window

63. Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest. 2014 Aug;146(2):309-17.Резюме external link opens in a new window

64. Wedzicha JA, Banerji D, Chapman KR, et al; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016 Jun 9;374(23):2222-34.Повний текст external link opens in a new windowРезюме external link opens in a new window

65. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep;124(3):834-43.Резюме external link opens in a new window

66. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698-702.Повний текст external link opens in a new windowРезюме external link opens in a new window

67. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005 Dec;60(12):992-7.Резюме external link opens in a new window

68. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002991.Повний текст external link opens in a new windowРезюме external link opens in a new window

69. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013 Nov;68(11):1029-36.Повний текст external link opens in a new windowРезюме external link opens in a new window

70. Festic E, Bansal V, Gupta E, et al. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD. 2016 Jun;13(3):312-26.Повний текст external link opens in a new windowРезюме external link opens in a new window

71. Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet. 2009 Aug 29;374(9691):668-70.Резюме external link opens in a new window

72. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115.Повний текст external link opens in a new windowРезюме external link opens in a new window

73. Dong YH, Chang CH, Lin Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014 Jun;145(6):1286-97.Резюме external link opens in a new window

74. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Sep 19;(9):CD002309.Повний текст external link opens in a new windowРезюме external link opens in a new window

75. Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015 Oct 26;5(10):e009183.Повний текст external link opens in a new windowРезюме external link opens in a new window

76. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD006829.Повний текст external link opens in a new windowРезюме external link opens in a new window

77. Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Aug 30;(8):CD006826.Повний текст external link opens in a new windowРезюме external link opens in a new window

78. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73.Резюме external link opens in a new window

79. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017 May 13;389(10082):1919-29.Резюме external link opens in a new window

80. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018 Mar 17;391(10125):1076-84.Резюме external link opens in a new window

81. Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-46.Повний текст external link opens in a new windowРезюме external link opens in a new window

82. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018 May 3;378(18):1671-80.Резюме external link opens in a new window

83. Rojas-Reyes MX, García Morales OM, Dennis RJ, et al. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008532.Повний текст external link opens in a new windowРезюме external link opens in a new window

84. Lenferink A, Brusse-Keizer M, van der Valk PD, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Aug 4;(8):CD011682.Повний текст external link opens in a new windowРезюме external link opens in a new window

85. Jolly K, Sidhu MS, Hewitt CA, et al. Self management of patients with mild COPD in primary care: randomised controlled trial. BMJ. 2018 Jun 13;361:k2241.Повний текст external link opens in a new windowРезюме external link opens in a new window

86. Lahham A, McDonald CF, Holland AE. Exercise training alone or with the addition of activity counseling improves physical activity levels in COPD: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2016 Dec 8;11:3121-36.Повний текст external link opens in a new windowРезюме external link opens in a new window

87. Vooijs M, Siemonsma PC, Heus I, et al. Therapeutic validity and effectiveness of supervised physical exercise training on exercise capacity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Clin Rehabil. 2016 Nov;30(11):1037-48.Резюме external link opens in a new window

88. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):47-55.Повний текст external link opens in a new windowРезюме external link opens in a new window

89. Hoogendoorn M, Feenstra TL, Hoogenveen RT, et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010 Aug;65(8):711-8.Резюме external link opens in a new window

90. Warnier MJ, van Riet EE, Rutten FH, et al. Smoking cessation strategies in patients with COPD. Eur Respir J. 2013 Mar;41(3):727-34.Резюме external link opens in a new window

91. van Eerd EA, van der Meer RM, van Schayck OC, et al. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Aug 20;(8):CD010744.Повний текст external link opens in a new windowРезюме external link opens in a new window

92. Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jan 24;(1):CD001390.Повний текст external link opens in a new windowРезюме external link opens in a new window

93. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Jun 26;(6):CD002733.Повний текст external link opens in a new windowРезюме external link opens in a new window

94. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Jul 29;(7):CD001287.Повний текст external link opens in a new windowРезюме external link opens in a new window

95. Osadnik CR, McDonald CF, Miller BR, et al. The effect of positive expiratory pressure (PEP) therapy on symptoms, quality of life and incidence of re-exacerbation in patients with acute exacerbations of chronic obstructive pulmonary disease: a multicentre, randomised controlled trial. Thorax. 2014 Feb;69(2):137-43.Резюме external link opens in a new window

96. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009 Mar 26;360(13):1329-35.Резюме external link opens in a new window

97. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest. 2000 Apr;117(4):976-83.Резюме external link opens in a new window

98. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2008 Dec 16;149(12):869-78.Резюме external link opens in a new window

99. Neves LF, Reis MH, Gonçalves TR. Home or community-based pulmonary rehabilitation for individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Cad Saude Publica. 2016 Jun 20;32(6):S0102-311X2016000602001.Повний текст external link opens in a new windowРезюме external link opens in a new window

100. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793.Повний текст external link opens in a new windowРезюме external link opens in a new window

101. Greening NJ, Williams JE, Hussain SF, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. 2014 Jul 8;349:g4315.Повний текст external link opens in a new windowРезюме external link opens in a new window

102. Marciniuk DD, Brooks D, Butcher S, et al. Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease - practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can Respir J. 2010 Jul-Aug;17(4):159-68.Резюме external link opens in a new window

103. Puhan MA, Gimeno-Santos E, Cates CJ, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec 8;(12):CD005305.Повний текст external link opens in a new windowРезюме external link opens in a new window

104. Celli BR, MacNee W, Agusti A, et al; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 Jun;23(6):932-46.Повний текст external link opens in a new windowРезюме external link opens in a new window

105. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003 Nov 5;290(17):2301-12.Повний текст external link opens in a new windowРезюме external link opens in a new window

106. Ekström M, Ahmadi Z, Bornefalk-Hermansson A, et al. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. Cochrane Database Syst Rev. 2016 Nov 25;(11):CD006429.Повний текст external link opens in a new windowРезюме external link opens in a new window

107. van Agteren JE, Hnin K, Grosser D, et al. Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Feb 23;(2):CD012158.Повний текст external link opens in a new windowРезюме external link opens in a new window

108. van Agteren JE, Carson KV, Tiong LU, et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev. 2016 Oct 14;(10):CD001001.Повний текст external link opens in a new windowРезюме external link opens in a new window

109. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004 Jun 24;350(26):2689-97.Резюме external link opens in a new window

110. Klooster K, Slebos DJ, Zoumot Z, et al. Endobronchial valves for emphysema: an individual patient-level reanalysis of randomised controlled trials. BMJ Open Respir Res. 2017 Nov 2;4(1):e000214.Повний текст external link opens in a new windowРезюме external link opens in a new window

111. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15.Повний текст external link opens in a new windowРезюме external link opens in a new window

112. Carlucci A, Guerrieri A, Nava S. Palliative care in COPD patients: is it only an end-of-life issue? Eur Respir Rev. 2012 Dec 1;21(126):347-54.Повний текст external link opens in a new windowРезюме external link opens in a new window

113. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014 Jan 30;348:g445.Повний текст external link opens in a new windowРезюме external link opens in a new window

114. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016 Oct 20;(10):CD007354.Повний текст external link opens in a new windowРезюме external link opens in a new window

115. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54.Повний текст external link opens in a new windowРезюме external link opens in a new window

116. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1171-8.Резюме external link opens in a new window

117. Niewoehner DE, Erbland ML, Deupree RH, et al; Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999 Jun 24;340(25):1941-7.Повний текст external link opens in a new windowРезюме external link opens in a new window

118. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60.Резюме external link opens in a new window

119. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002 Mar 1;165(5):698-703.Повний текст external link opens in a new windowРезюме external link opens in a new window

120. Osadnik CR, McDonald CF, Jones AP, et al. Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD008328.Повний текст external link opens in a new windowРезюме external link opens in a new window

121. Tang CY, Taylor NF, Blackstock FC. Chest physiotherapy for patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease (COPD): a systematic review. Physiotherapy. 2010 Mar;96(1):1-13.Резюме external link opens in a new window

122. Hill K, Patman S, Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. Chron Respir Dis. 2010;7(1):9-17.Резюме external link opens in a new window

123. Cross J, Elender F, Barton G, et al. A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX). Health Technol Assess. 2010 May;14(23):1-147.Повний текст external link opens in a new windowРезюме external link opens in a new window

124. Lightowler JV, Wedzicha JA, Elliott MW, et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ. 2003 Jan 25;326(7382):185.Повний текст external link opens in a new windowРезюме external link opens in a new window

125. Keenan SP, Sinuff T, Burns KE, et al. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CMAJ. 2011 Feb 22;183(3):E195-214.Повний текст external link opens in a new windowРезюме external link opens in a new window

126. Barreiro TJ, Gemmel DJ. Noninvasive ventilation. Crit Care Clin. 2007 Apr;23(2):201-22.Резюме external link opens in a new window

127. Smith TA, Davidson PM, Lam LT, et al. The use of non-invasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease; a systematic review. Respirology. 2012 Feb;17(2):300-7.Резюме external link opens in a new window

128. Sun YQ, Wei Q, Liu Z. Efficacy of continuous positive airway pressure in the treatment of chronic obstructive pulmonary disease combined with respiratory failure. Am J Ther. 2016 Mar-Apr;23(2):e439-50.Резюме external link opens in a new window

129. Antón A, Güell R, Gómez J, et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic airflow limitation. Chest. 2000 Mar;117(3):828-33.Резюме external link opens in a new window

130. Koh Y. Ventilatory management in patients with chronic airflow obstruction. Crit Care Clin. 2007 Apr;23(2):169-81.Резюме external link opens in a new window

131. Rodríguez-Roisin R. COPD exacerbations. 5: management. Thorax. 2006 Jun;61(6):535-44.Повний текст external link opens in a new windowРезюме external link opens in a new window

132. Breen D, Churches T, Hawker F, et al. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax. 2002 Jan;57(1):29-33.Повний текст external link opens in a new windowРезюме external link opens in a new window

133. McCurdy BR. Noninvasive positive pressure ventilation for acute respiratory failure patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12(8):1-102.Повний текст external link opens in a new windowРезюме external link opens in a new window

134. Udwadia ZF, Santis GK, Steven MH, et al. Nasal ventilation to facilitate weaning in patients with chronic respiratory insufficiency. Thorax. 1992 Sep;47(9):715-8.Повний текст external link opens in a new windowРезюме external link opens in a new window

135. Li PJ, Wang T, Xiao J, et al. Efficacy of two noninvasive weaning strategies in intubated patients with chronic obstructive pulmonary disease: a meta-analysis and indirect treatment comparison. Heart Lung. 2016 Mar-Apr;45(2):132-9.Резюме external link opens in a new window

136. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006 Mar;61(3):189-95.Повний текст external link opens in a new windowРезюме external link opens in a new window

137. Decramer ML, Hanania NA, Lötvall JO, et al. The safety of long-acting beta2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:53-64.Повний текст external link opens in a new windowРезюме external link opens in a new window

138. Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001104.Повний текст external link opens in a new windowРезюме external link opens in a new window

139. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002876.Повний текст external link opens in a new windowРезюме external link opens in a new window

140. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34.Резюме external link opens in a new window

141. Williams TJ, Grossman RF, Maurer JR. Long-term functional follow-up of lung transplant recipients. Clin Chest Med. 1990 Jun;11(2):347-58.Резюме external link opens in a new window

142. Gross CR, Savik K, Bolman RM 3rd, et al. Long-term health status and quality of life outcomes of lung transplant recipients. Chest. 1995 Dec;108(6):1587-93.Резюме external link opens in a new window

143. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998 Jan 3;351(9095):24-7.Резюме external link opens in a new window

144. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015 Mar 7;385(9971):857-66.Резюме external link opens in a new window

145. Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE[2]SPOND). A randomized clinical trial. Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67.Резюме external link opens in a new window

146. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503-8.Повний текст external link opens in a new windowРезюме external link opens in a new window

147. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 Aug 25;365(8):689-98.Резюме external link opens in a new window

148. Brindicci C, Ito K, Torre O, et al. Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients. Chest. 2009 Feb;135(2):353-67.Резюме external link opens in a new window

149. Fowdar K, Chen H, He Z, et al. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review. Heart Lung. 2017 Mar-Apr;46(2):120-8.Резюме external link opens in a new window

150. Pavasini R, Biscaglia S, d'Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016 Aug;13(4):509-14.Резюме external link opens in a new window

151. Malhotra S, Man SF, Sin DD. Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.Резюме external link opens in a new window

152. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest. 2009 Sep;136(3):734-43.Резюме external link opens in a new window

153. Criner GJ, Connett JE, Aaron SD, et al; COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014 Jun 5;370(23):2201-10.Повний текст external link opens in a new windowРезюме external link opens in a new window

154. Zhang W, Zhang Y, Li CW, et al. Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest. 2017 Dec;152(6):1159-68.Резюме external link opens in a new window

155. Levinson B, Gertner J. Randomized study of the efficacy and safety of SUN11031 (synthetic human ghrelin) in cachexia associated with chronic obstructive pulmonary disease. e-SPEN J. 2012 Oct;7(5):e171-5.Повний текст external link opens in a new window

156. Hind M, Stinchcombe S. Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. Curr Opin Investig Drugs. 2009 Nov;10(11):1243-50.Резюме external link opens in a new window

157. Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003 May 22;348(21):2059-73.Повний текст external link opens in a new windowРезюме external link opens in a new window

158. Valipour A, Herth FJ, Burghuber OC, et al. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. Eur Respir J. 2014 Feb;43(2):387-96.Резюме external link opens in a new window

159. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J. 2005 Jun;25(6):1084-106.Повний текст external link opens in a new windowРезюме external link opens in a new window

160. Sandford AJ, Silverman EK. Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax. 2002 Aug;57(8):736-41.Резюме external link opens in a new window

161. Laucho-Contreras ME, Polverino F, Tesfaigzi Y, et al. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD). Expert Opin Ther Targets. 2016 Jul;20(7):869-83.Повний текст external link opens in a new windowРезюме external link opens in a new window

162. Zider AD, Wang X, Buhr RG, et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017 Sep;152(3):494-501.Резюме external link opens in a new window

163. Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis. Medicine (Baltimore). 2016 Jul;95(28):e4225.Повний текст external link opens in a new windowРезюме external link opens in a new window

164. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.Повний текст external link opens in a new windowРезюме external link opens in a new window

165. Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J. 2014 Feb;43(2):397-408.Резюме external link opens in a new window

166. Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017 Jan 31;26(143):160070.Повний текст external link opens in a new windowРезюме external link opens in a new window

167. Stolz D, Meyer A, Rakic J, et al. Mortality risk prediction in COPD by a prognostic biomarker panel. Eur Respir J. 2014 Dec;44(6):1557-70.Резюме external link opens in a new window

168. Almagro P, Soriano JB, Cabrera FJ, et al; Working Group on COPD, Spanish Society of Internal Medicine. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014 May;145(5):972-80.Резюме external link opens in a new window

169. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005 Aug;26(2):234-41.Повний текст external link opens in a new windowРезюме external link opens in a new window

170. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Nov 26;300(20):2407-16.Повний текст external link opens in a new windowРезюме external link opens in a new window

171. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009 Feb 9;169(3):219-29.Повний текст external link opens in a new windowРезюме external link opens in a new window

172. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001 Apr 3;134(7):600-20.Резюме external link opens in a new window

173. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest. 1991 Mar;99(3):715-23.Резюме external link opens in a new window

174. John M, Lange A, Hoernig S, et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol. 2006 Aug 28;111(3):365-70.Резюме external link opens in a new window

175. Chambellan A, Chailleux E, Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long term oxygen therapy. Chest. 2005 Sep;128(3):1201-8.Резюме external link opens in a new window

176. Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013 May;107(5):637-48.Резюме external link opens in a new window

177. Lee JS, Park DA, Hong Y, et al. Systematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitis. Int J Tuberc Lung Dis. 2013 Feb;17(2):153-62.Резюме external link opens in a new window

178. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013 Nov 28;(11):CD009764.Повний текст external link opens in a new windowРезюме external link opens in a new window

Використання цього контенту підпадає під нашу відмову від відповідальності